Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 2, 2003, Pages 175-183

  Poirier, Miriam C ^a,e   Divi, Rao L ^a   Al Harthi, Lena ^b   Olivero, Ofelia A ^a   Nguyen, Vi ^a   Walker, Brettania ^a   Landay, Alan L ^b   Walker, Vernon E ^c   Charurat, Manhattan ^d   Blattner, William A ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^d INSTITUTE OF HUMAN VIROLOGY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Lymphocytes; Mitochondrial DNA; Nucleoside reverse transcriptase inhibitor; Telomere; Women and Infants Transmission Study

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CELL NUCLEUS DNA; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; RNA 18S; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

18S RNA GENE; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; GENE; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE; LOSS OF MITOCHONDRIAL DNA AND TELOMERE INTEGRITY; MITOCHONDRIAL D LOOP GENE; MITOCHONDRIAL TOXICITY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PREGNANCY; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; TELOMERE; TELOMERE LENGTH; UMBILICAL CORD BLOOD;

EID: 0038078685     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200306010-00010     Document Type: Article

References (43)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
2. Sperling RS, Shapiro DE, Coombs RW, et al. Matemal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996;335:1621-1629.
3. Mofenson LM, Committee on Pediatric AIDS. Technical Report: Perinatal human immunodeficiency virus testing and prevention of transmission. Pediatrics. 2000;106:1-12.
4. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281:151-157.
5. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
6. Caselli D, Klersy C, de Martino M, et al. Human immunodeficiency virus-related cancer in children: incidence and treatment outcome - report of the Italian Register. J Clin Oncol. 2000;18:3854-3861.
7. Newschaffer CJ, Cocroft J, Anderson CE, et al. Prenatal zidovudine use and congenital anomalies in a medicaid population. J Acquir Immune Defic Syndr. 2000;24:249-256.
8. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:463-467.
9. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
10. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst. 1997;89:1602-1608.
11. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990; 322:1098-1105.
12. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1:417-422.
13. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther. 1998;20:2-25.
14. Dagan T, Sable C, Bray J, et al. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? Mitochondrion. 2002;1:397-412.
15. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS. 2001;15:795-797.
16. Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS. 2000;14:2723-2730.
17. Mhiri C, Baudrimont M, Bonne G, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol. 1991;29:606-614.
18. Tomelleri G, Tonin P, Spadaro M, et al. AZT-induced mitochondrial myopathy. Ital J Neurol Sci. 1992;13:723-728.
19. Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol (Berl). 1995;90:1-6.
20. Chen SC, Barker SM, Mitchell DH, et al. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection. Pathology. 1992;24: 109-111.
21. Schroder JM, Bertram M, Schnabel R, et al. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine. Acta Neuropathol (Berl). 1992;85: 39-47.
22. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000;25:261-268.
23. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group, N Engl J Med. 2000;343:759-766.
24. Olivero OA, Poirier MC. Preferential incorporation of 3′-azido2′,3′-dideoxythymidine (AZT) into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells. Mol Carcinog. 1993;8:81-88.
25. Gomez DE, Kassim A, Olivero OA. Preferential incorporation of 3′-Azido-2′,3′-dideoxythymidine (AZT) in telomeric sequences of CHO cells. Int J Oncol. 1995;7:1057-1060.
26. Gomez DE. Tejera AM, Olivero OA. Irreversible telomere shortening by 3′-azido-2′, 3′-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun. 1998;246:107-110.
27. Diwan BA, Riggs CW, Logsdon D, et al. Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice. Toxicol Appl Pharmacol. 1999;15:82-99.
28. Sheon A, Fox H, Rich K. For the women and infants transmission study group. The women and infants transmission study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data. J Womens Health. 1996;5:69-78.
29. Walker VE, Wade N, Abrams EJ et al. Observational cohort study of the genotoxic risks arising from perinatal NRTI therapies. Environ Mol Mutagen. 2001;37(s32):77.
30. Divi RL, Beland FA, Fu PP, et al. Highly-sensitive chemiluminescence immunoassay for benzo[a]pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring. Carcinogenesis. 2002;23:2043-2049.
31. Diggle PJ. An approach to the analysis of repeated measures. Biometrics. 1998;45:1255-1258.
32. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med. 2000;19: 1793-1819.
33. Veal GJ, Hoggard PG, Barry MG, et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS. 1996;10:546-548.
34. Gonzalez CM, Larripa I. Genotoxicity of azidothymidine (AZT) in in vitro systems. Mutat Res. 1994;321:113-118.
35. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res. 1994;74:344-348.
36. Feng JY, Johnson AA, Johnson KA, et al. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem. 2001;276:23832-23837.
37. Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr. 2002;29: 117-121.
38. Divi RL, Walker VE, Gerschenson M, et al. Mitochondrial damage in cord blood and umbilical cord lymphocytes of infants exposed in utero to Zidovudine and Lamivudine. Environ Mol Mutagen. 2002;39(s33):23.
39. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.
40. Cherry CL, Gahan ME, McArthur JC, et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr. 2002;30:271-277.
41. Olivero OA, Shearer GM, Chougnet CA, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS. 1999;13:919-925.
42. Bigbee WL, Ness RB, Bass DC, et al. Glycophorin A (GPA) locus somatic mutations in umbilical cord blood erythroid cells of infants exposed in utero to NRTIS. Environ Mol Mutagen. 2001;37(s32): 22.
43. Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr. 2002;29:323-329.